. 2021 Dec 7;113(2):784–795. doi: 10.1111/cas.15207

TABLE 1.

Association between Schlafen 11 (SLFN11) expression and clinicopathologic characteristics in bladder carcinoma (BC) patients (n = 120)

Patient characteristics		SLFN11 expression, n (%)		P value
Patient characteristics		Positive	Negative	P value
Unresectable locally advanced or metastatic BC patients with platinum‐based chemotherapy (n = 50)
Sex	Male	17 (46)	20 (54)	.333
Sex	Female	8 (62)	5 (38)	.333
Age, y	≤70	10 (40)	15 (60)	.157
Age, y	>70	15 (60)	10 (40)	.157
Cellular atypism classification	Low grade	3 (50)	3 (50)	1.000
Cellular atypism classification	High grade	22 (50)	22 (50)	1.000
Clinical TNM stage	Stage II	7 (70)	3 (30)	.329
	Stage III	4 (44)	5 (56)
	Stage IV	13 (43)	17 (57)
First‐line chemotherapy regimen	GC or MVAC	22 (49)	23 (51)	.637
First‐line chemotherapy regimen	GCa	3 (60)	2 (40)	.637
Response to chemotherapy	SD or PD	14 (48)	15 (52)	.775
Response to chemotherapy	PR or CR	11 (52)	10 (48)	.775
BC patients treated by radical cystectomy without chemotherapy (n = 70)
Sex	Male	18 (36)	32 (64)	.145
Sex	Female	11 (55)	9 (45)	.145
Age, y	≤70	9 (33)	18 (67)	.276
Age, y	>70	20 (47)	23 (53)	.276
Cellular atypism classification	Low grade	1 (20)	4 (80)	.313
Cellular atypism classification	High grade	28 (43)	37 (57)	.313
T classification	Ta/Tis/1	10 (36)	18 (64)	.428
T classification	T2/3/4	19 (45)	23 (55)	.428
Lymphatic invasion	Negative	20 (41)	28 (58)	.952
Lymphatic invasion	Positive	9 (41)	13 (59)	.952
Vascular invasion	Negative	27 (42)	36 (57)	.467
Vascular invasion	Positive	2 (29)	5 (71)	.467
N classification	N0	25 (44)	32 (56)	.973
N classification	N1/2/3	4 (44)	5 (56)	.973
TNM stage	0/I/II	14 (34)	27 (66)	.141
TNM stage	III/IV	15 (52)	14 (48)	.141

Abbreviations: CR, complete response; GC, gemcitabine and cisplatin; GCa, gemcitabine and carboplatin; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; PD, progressive disease; PR, partial response; SD, stable disease; Ta, noninvasive papillary carcinoma; Tis, carcinoma in situ.